Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin

An implication of synergy

Wen Yue, Tao Wang, Emmanuel Zachariah, Yong Lin, Chung S. Yang, Qing Xu, Robert S. DiPaola, Xiang Lin Tan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Metformin and aspirin have been studied extensively as cancer preventative and therapeutic agents. However, the underlying molecular mechanisms for the inhibitory effects of pancreatic cancer development remain undefined. To gain further insight into their biological function in pancreatic cancer, we conducted a transcriptomic analysis using RNA sequencing to assess the differential gene expression induced by metformin (5 mM) and aspirin (2 mM), alone or in combination, after treatment of PANC-1 cells for 48 hours. Compared to an untreated control, metformin down-regulated 58 genes and up-regulated 91 genes, aspirin down-regulated 12 genes only, while metformin plus aspirin down-regulated 656 genes and up-regulated 449 genes (fold-change > 2, P <10-5). Of the top 10 genes (fold-change > 10, P <10-10) regulated by metformin plus aspirin, PCDH18, CCL2, RASL11A, FAM111B and BMP5 were down-regulated ≥20-fold, while NGFR, NPTX1, C7orf57, MRPL23AS1 and UNC5B were up-regulated ≥10-fold. Ingenuity Pathway Analysis (IPA) revealed that the pathways, "cholesterol biosynthesis", "cell cycle: G1/S checkpoint regulation", and "axonal guidance signaling" were the most statistically significant pathways modulated by metformin plus aspirin. Although the results need further functional validation, these data provide the first evidence for the synergistic action between metformin and aspirin in modulating the transcriptional profile of pancreatic cancer cells.

Original languageEnglish (US)
Article number13390
JournalScientific Reports
Volume5
DOIs
StatePublished - Aug 21 2015

Fingerprint

Metformin
Pancreatic Neoplasms
Aspirin
Genes
G1 Phase Cell Cycle Checkpoints
RNA Sequence Analysis
Cholesterol
Gene Expression
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin : An implication of synergy. / Yue, Wen; Wang, Tao; Zachariah, Emmanuel; Lin, Yong; Yang, Chung S.; Xu, Qing; DiPaola, Robert S.; Tan, Xiang Lin.

In: Scientific Reports, Vol. 5, 13390, 21.08.2015.

Research output: Contribution to journalArticle

Yue, Wen ; Wang, Tao ; Zachariah, Emmanuel ; Lin, Yong ; Yang, Chung S. ; Xu, Qing ; DiPaola, Robert S. ; Tan, Xiang Lin. / Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin : An implication of synergy. In: Scientific Reports. 2015 ; Vol. 5.
@article{41ba7c148f314a86877d7941e25eb387,
title = "Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin: An implication of synergy",
abstract = "Metformin and aspirin have been studied extensively as cancer preventative and therapeutic agents. However, the underlying molecular mechanisms for the inhibitory effects of pancreatic cancer development remain undefined. To gain further insight into their biological function in pancreatic cancer, we conducted a transcriptomic analysis using RNA sequencing to assess the differential gene expression induced by metformin (5 mM) and aspirin (2 mM), alone or in combination, after treatment of PANC-1 cells for 48 hours. Compared to an untreated control, metformin down-regulated 58 genes and up-regulated 91 genes, aspirin down-regulated 12 genes only, while metformin plus aspirin down-regulated 656 genes and up-regulated 449 genes (fold-change > 2, P <10-5). Of the top 10 genes (fold-change > 10, P <10-10) regulated by metformin plus aspirin, PCDH18, CCL2, RASL11A, FAM111B and BMP5 were down-regulated ≥20-fold, while NGFR, NPTX1, C7orf57, MRPL23AS1 and UNC5B were up-regulated ≥10-fold. Ingenuity Pathway Analysis (IPA) revealed that the pathways, {"}cholesterol biosynthesis{"}, {"}cell cycle: G1/S checkpoint regulation{"}, and {"}axonal guidance signaling{"} were the most statistically significant pathways modulated by metformin plus aspirin. Although the results need further functional validation, these data provide the first evidence for the synergistic action between metformin and aspirin in modulating the transcriptional profile of pancreatic cancer cells.",
author = "Wen Yue and Tao Wang and Emmanuel Zachariah and Yong Lin and Yang, {Chung S.} and Qing Xu and DiPaola, {Robert S.} and Tan, {Xiang Lin}",
year = "2015",
month = "8",
day = "21",
doi = "10.1038/srep13390",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Transcriptomic analysis of pancreatic cancer cells in response to metformin and aspirin

T2 - An implication of synergy

AU - Yue, Wen

AU - Wang, Tao

AU - Zachariah, Emmanuel

AU - Lin, Yong

AU - Yang, Chung S.

AU - Xu, Qing

AU - DiPaola, Robert S.

AU - Tan, Xiang Lin

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Metformin and aspirin have been studied extensively as cancer preventative and therapeutic agents. However, the underlying molecular mechanisms for the inhibitory effects of pancreatic cancer development remain undefined. To gain further insight into their biological function in pancreatic cancer, we conducted a transcriptomic analysis using RNA sequencing to assess the differential gene expression induced by metformin (5 mM) and aspirin (2 mM), alone or in combination, after treatment of PANC-1 cells for 48 hours. Compared to an untreated control, metformin down-regulated 58 genes and up-regulated 91 genes, aspirin down-regulated 12 genes only, while metformin plus aspirin down-regulated 656 genes and up-regulated 449 genes (fold-change > 2, P <10-5). Of the top 10 genes (fold-change > 10, P <10-10) regulated by metformin plus aspirin, PCDH18, CCL2, RASL11A, FAM111B and BMP5 were down-regulated ≥20-fold, while NGFR, NPTX1, C7orf57, MRPL23AS1 and UNC5B were up-regulated ≥10-fold. Ingenuity Pathway Analysis (IPA) revealed that the pathways, "cholesterol biosynthesis", "cell cycle: G1/S checkpoint regulation", and "axonal guidance signaling" were the most statistically significant pathways modulated by metformin plus aspirin. Although the results need further functional validation, these data provide the first evidence for the synergistic action between metformin and aspirin in modulating the transcriptional profile of pancreatic cancer cells.

AB - Metformin and aspirin have been studied extensively as cancer preventative and therapeutic agents. However, the underlying molecular mechanisms for the inhibitory effects of pancreatic cancer development remain undefined. To gain further insight into their biological function in pancreatic cancer, we conducted a transcriptomic analysis using RNA sequencing to assess the differential gene expression induced by metformin (5 mM) and aspirin (2 mM), alone or in combination, after treatment of PANC-1 cells for 48 hours. Compared to an untreated control, metformin down-regulated 58 genes and up-regulated 91 genes, aspirin down-regulated 12 genes only, while metformin plus aspirin down-regulated 656 genes and up-regulated 449 genes (fold-change > 2, P <10-5). Of the top 10 genes (fold-change > 10, P <10-10) regulated by metformin plus aspirin, PCDH18, CCL2, RASL11A, FAM111B and BMP5 were down-regulated ≥20-fold, while NGFR, NPTX1, C7orf57, MRPL23AS1 and UNC5B were up-regulated ≥10-fold. Ingenuity Pathway Analysis (IPA) revealed that the pathways, "cholesterol biosynthesis", "cell cycle: G1/S checkpoint regulation", and "axonal guidance signaling" were the most statistically significant pathways modulated by metformin plus aspirin. Although the results need further functional validation, these data provide the first evidence for the synergistic action between metformin and aspirin in modulating the transcriptional profile of pancreatic cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84939825859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939825859&partnerID=8YFLogxK

U2 - 10.1038/srep13390

DO - 10.1038/srep13390

M3 - Article

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 13390

ER -